Who
Jennifer Lynne Fox
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Myriad Genetics; EVP, Ext Aff, GC, Corp Sec, Emergent BioSolutions.
In numbers
- Trades disclosed
- 31
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Mar 2022
- Last trade
- 3 Sep 2026
- Last filed
- 8 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 8 Sep 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $14K4,398 at $3.23 | filing |
| 3 Sep 2026filed 8 Sep 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $14K4,398 at $3.23 | filing |
| 13 Mar 2026filed 16 Mar 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $28K5,995 at $4.66 | filing |
| 13 Mar 2026filed 16 Mar 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $28K5,995 at $4.66 | filing |
| 12 Mar 2026filed 16 Mar 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —195,876 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —195,876 at $0.00 | filing |
| 3 Sep 2025filed 4 Sep 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $30K4,435 at $6.80 | filing |
| 13 Mar 2025filed 17 Mar 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —63,145 at $0.00 | filing |
| 3 Sep 2024filed 4 Sep 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —61,771 at $0.00 | filing |
| 11 Jul 2024filed 12 Jul 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 8 Jun 2024filed 11 Jun 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $15K2,376 at $6.19 | filing |
| 13 Mar 2024filed 15 Mar 2024 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 1 Mar 2024filed 4 Mar 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $2,383703 at $3.39 | filing |
| 29 Feb 2024filed 4 Mar 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $13K4,103 at $3.23 | filing |
| 23 Feb 2024filed 27 Feb 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $627229 at $2.74 | filing |
| 11 Nov 2023filed 14 Nov 2023 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $826413 at $2.00 | filing |
| 9 Jun 2023filed 13 Jun 2023 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,231 at $0.00 | filing |
| 9 Jun 2023filed 13 Jun 2023 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —24,616 at $0.00 | filing |
| 9 Jun 2023filed 13 Jun 2023 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —49,231 at $0.00 | filing |
| 2 Mar 2023filed 6 Mar 2023 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,308 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.